GSK 249320, identified by its CAS number 1233953-61-1, is a chemical compound that has been studied primarily for its potential therapeutic applications. It belongs to a class of compounds that may exhibit properties relevant to the treatment of various diseases, particularly in the context of neurological or psychiatric disorders. The substance is characterized by its specific molecular structure, which influences its biological activity and interaction with target receptors in the body. While detailed pharmacological data may vary, compounds like GSK 249320 are typically evaluated for their efficacy, safety, and mechanism of action through preclinical and clinical studies. Additionally, its solubility, stability, and metabolic profile are important characteristics that determine its suitability for development as a pharmaceutical agent. As research progresses, more information regarding its specific applications and effects may become available, contributing to a better understanding of its role in medicinal chemistry.

GSK 249320

1233953-61-1: GSK 249320, identified by its CAS number 1233953-61-1, is a chemical compound that has been studied primarily for its potential therapeutic applications. It belongs to a class of compounds that may exhibit properties relevant to the treatment of various diseases, particularly in the context of neurological or psychiatric disorders. The substance is characterized by its specific molecular structure, which influences its biological activity and interaction with target receptors in the body. While detailed pharmacological data may vary, compounds like GSK 249320 are typically evaluated for their efficacy, safety, and mechanism of action through preclinical and clinical studies. Additionally, its solubility, stability, and metabolic profile are important characteristics that determine its suitability for development as a pharmaceutical agent. As research progresses, more information regarding its specific applications and effects may become available, contributing to a better understanding of its role in medicinal chemistry.

Ziltivekimab (MEDI 5117) is a CHO-expressed humanized monoclonal antibody targeting IL-6/IFNb2 for use in immune system diseases.

Refanezumab

Anti-myelin-associated glycoprotein monoclonal antibody; recovery of motor function after stroke

CAS 1233953-61-1

GSK 249320

Refanezumab

Ref: TM-T77388

Refanezumab

Ref: 3D-CLA1416